Research programme: vascular protectants - AtheroGenics
Alternative Names: AGI-2048; AGI-2636; AGI-series for respiratory diseases; v-protectantsLatest Information Update: 11 May 2009
At a glance
- Originator AtheroGenics
- Class Small molecules
- Mechanism of Action Antioxidants; Vascular cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Asthma; Rheumatoid arthritis
Most Recent Events
- 14 Jun 2005 Data presented at the 101st International Conference of the American Thoracic Society (ATS-2005) have been added to the Obstructive airways disease pharmacodynamics section ,
- 14 Oct 2004 This programme is still in active development for Rheumatoid arthritis
- 14 Nov 2003 Preclinical trials in Rheumatoid arthritis in USA (PO)